FDA warns shorter name of new Roche cancer drug may cause confusion
(Reuters) – The Food and Drug Administration warned on Monday that using a shorter name for Roche’s new breast cancer drug Kadcyla may lead to the treatment being confused with an older therapy and cause potential harm to patients. The FDA issued a warning on its website saying that some third-party publications, health information systems and websites were incorrectly using a truncated version of Kadcyla’s generic name. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply